For Quick Alerts
For Daily Alerts

USFDA Completes inspection of Lupin's Goa facility

By Religare

Leading pharma company, Lupin Limited (Lupin) has said that there has been successful completion of a PAI inspection (Prior Approval Inspection) carried out by the US FDA at its Goa manufacturing facility without any observations. The inspection which started on Monday, July 17th concluded on July 21st.

USFDA Completes inspection of Lupin's Goa facility
Lupin: Quotes, News
BSE 755.85BSE Quote8.75 (1.16%)
NSE 756.50NSE Quote9.15 (1.21%)
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 4th and the 6th largest generics pharmaceutical company by market capitalization and revenues globally. The Company is the 4th largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT March 2017); the 2nd largest Indian pharmaceutical company by global revenues; the 6th largest generic pharmaceutical player in Japan and the 6th largest company in Indian Pharmaceutical Market (Quintiles IMS MAT March 2017).

Meanwhile, shares of the company were trading at Rs 1152 apiece, up 0.80 per cent from the previous close at 09:30 hours on BSE.

Read more about: lupin
Company Search
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more